Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05990920
Other study ID # SNK02-202
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date August 23, 2023
Est. completion date December 2024

Study information

Verified date September 2023
Source NKGen Biotech, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are: - Is SNK02 safety and tolerable when administered weekly as an intravenous infusion - What is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 6
Est. completion date December 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically confirmed diagnosis of refractory cancer that has failed at least prior line of conventional standard of care therapy. - Diagnosed with any histologically confirmed malignancy whose disease is confirmed to be metastatic and/or unresectable for which standard curative or beneficial treatments are no longer effective. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - = 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational). - = 2 weeks since prior palliative radiotherapy. - Complete recovery to baseline or Grade 1 NCI CTCAE v5.0 from AE of prior surgery, radiotherapy, endocrine therapy, and other therapy as applicable, with exception of grade 2 alopecia from prior chemotherapy. - Adequate bone marrow function: - Neutrophils: = 1.5 K/µL without colony-stimulating factor support - Platelet Count: = 100 K/µL - Hemoglobin: = 9.0 g/dL without need for hematopoietic growth factor or transfusion support - No ongoing transfusion requirements - Adequate hepatic function: - Serum total bilirubin = 1.5 × upper limit of normal (ULN), does not apply to patients with Gilbert's syndrome - Serum albumin = 3.0 g/dL - ALT and AST = 2.5 × ULN, unless hepatic metastases are present then < 5 x ULN - Adequate renal function with creatinine = 2.0 mg/dL. - Coagulation: INR or aPTT =1.5 X ULN unless the subject is receiving anticoagulant therapy. - Adequate pulmonary function as assessed by pulse oximetry (>92% oxygen saturation on room air). - Negative pregnancy test for women of childbearing potential (i.e., all women except those who are post menopause for = 1 year or who have a history of hysterectomy or surgical sterilization) and agree to use of effective contraception (hormonal or barrier method of birth control) during study. - Male participants and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Exclusion Criteria: - Pregnant and/or lactating females. - Life expectancy of less than three months. - Currently being treated by "biological therapy" as defined by the National Cancer Institute (https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact- sheet) Examples include checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies, treatment vaccines, cytokines, CAR-T therapy, and natural killer (NK) cell therapy. - Participants that are actively positive for COVID. - Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring immunosuppressive therapy, with exception to the following: - intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); - Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; - Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). - Prior clinical trial requiring participant to receive an investigational drug within four weeks of enrollment. - Live vaccine within 30 days prior to enrollment. - Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. - Mental or psychological illness preventing cooperation with treatment, efficacy evaluations. - Participants who have undergone prior organ transplantation, including allogeneic stem-cell transplantation.

Study Design


Intervention

Biological:
SNK02
SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.

Locations

Country Name City State
United States Angeles Clinic and Research Institute Los Angeles California
United States Sarcoma Oncology Center Santa Monica California

Sponsors (1)

Lead Sponsor Collaborator
NKGen Biotech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with dose-limiting toxicity as assessed by labs, PE and AEs Evaluate the safety and tolerability of SNK02 assessed by labs, PE and AEs 4 weeks
Primary MTD and/or RP2D Determine the maximum tolerated dose or the ready for Phase 2 dose of SNK02 8 weeks
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Evaluate the safety and tolerability of SNK02 assessed by labs, PE and AEs 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2